ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2016
Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils.
Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort.The Journal of allergy and clinical immunology · 2020Trial
- Is it time for a simplified method to evaluate airway eosinophilia?ERJ open research · 2026Article
- Neutrophilic Asthma-From Mechanisms to New Perspectives of Therapy.Journal of clinical medicine · 2025Review
- Precision Medicine in Asthma: The Role of Biomarkers.ImmunoTargets and therapy · 2025Review
- Angiogenesis Factors as Emerging Circulating Biomarkers in Asthma.Allergy, asthma & immunology research · 2025Review
- Review
- Utility of biomarkers in the diagnosis and monitoring of asthmatic children.The World Allergy Organization journal · 2023Review
- A Multi-Center Study of the Prevalence and Characteristics of Eosinophilic Phenotype and High IgE Levels Among Chinese Patients with Severe Asthma.Journal of asthma and allergy · 2023Article
- Article
- ITGB4 deficiency induces mucus hypersecretion by upregulating MUC5AC in RSV-infected airway epithelial cells.International journal of biological sciences · 2022Article
- Protective effects of glaucocalyxin A on the airway of asthmatic mice.Open medicine (Warsaw, Poland) · 2022Article
- Immune responses and exacerbations in severe asthma.Current opinion in immunology · 2021Review
- Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review.Metabolites · 2021Review
- Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab.Respirology case reports · 2021Article
- Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program.American journal of respiratory and critical care medicine · 2021Article
- Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis.Frontiers in pharmacology · 2021Review
- Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma?Physiological reviews · 2020Review
- A bispecific antibody strategy to target multiple type 2 cytokines in asthma.The Journal of allergy and clinical immunology · 2018Article
- Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland.European clinical respiratory journal · 2018Article
- Sputum cell counts to manage prednisone-dependent asthma: effects on FEVAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAirway inflammatory phenotyping is increasingly applied to subjects with asthma. However, its relationship to clinical outcomes in difficult asthma is incompletely elucidated.
objectiveThe goal of our study was to determine the relationship between exacerbation rates and phenotypes of difficult asthma based on the longitudinal measures of sputum eosinophils and neutrophils.
methodsSubjects in the longitudinal observational study from two tertiary care centres that completed 1 year of observation and provided at least three sputum samples were classified by inflammatory phenotypes using previously established thresholds. Kaplan-Meier curves and univariable and multivariable Cox proportional hazard models were used to determine the association between inflammatory phenotypes and exacerbation rate.
resultsDuring the study, 115 exacerbations occurred in 73 severe asthmatic subjects. Subjects with the persistently eosinophilic phenotype had a significantly shorter time to first exacerbation and greater risk of exacerbation over a 1-year period than those with the non-eosinophilic phenotype based on the univariable and multivariable Cox proportional hazard model (hazard ratio [HR], 3.24; 95% confidence interval [CI], 1.35-7.72; adjusted HR, 3.90; 95% CI, 1.34-11.36). No significant differences in time to first exacerbation or exacerbation risk over a 1-year period were observed among the neutrophilic phenotypes.
conclusionsThe persistent eosinophilic phenotype is associated with increased exacerbation risk compared with the non-eosinophilic phenotype in severe asthma. No differences in time to first exacerbation or exacerbation risk over a 1-year period were detected among neutrophilic phenotypes.
Indexed as
Identifiers
27214328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.